Genomic Applications Partnership Program (GAPP)

GAPP Investment Strategy and Guidelines
Timelines

Expression of Interest Forms

GAPP Full Proposal Forms

GAPP Webinars

Investment Strategy and Guidelines

Update to GAPP Application Process

1. Overview

The Genomic Applications Partnership Program (GAPP) represents a key element in Genome Canada’s strategic plan towards funding downstream research and development (R&D) projects that are driven by challenges and opportunities facing users of genomics based technologies. For the purpose of this program, “Users” include the various stakeholders that have an interest in “pulling” technologies and other results of genomics research from academia to market and application, including industry, government, not-for-profits, and other organizations.

Genome Canada is a catalyst for developing and applying genomic sciences that create economic wealth and social benefit for Canadians. Genome Canada builds bridges between government, academia and industry to forge a genomics-based public-private innovation enterprise focused on key life science sectors (agriculture, fisheries, forestry, energy, mining, environment, and human health). Genome Canada and the regional Genome Centres have made significant investments in large-scale genomics1 research and leading-edge technologies which has allowed Canada to become a leader in the field of genomics. We are now focusing a significant amount of effort to build and improve ways of translating discoveries into new applications by enabling the transfer of knowledge and technologies from Academia to the User community in ways that will maximize the impact of this initial investment and lead to economic and social benefits for Canada.

2. Objectives

The GAPP aims to:

  • Promote the application of genomics-derived solutions to address key sector challenges or opportunities facing Users - User “pull”;
  • Promote commercialization of genomics technologies by enabling the transfer of genomics-derived solutions from Academia to Users as well as de-risking and incentivizing follow-on investment from public and private partners;
  • Increase the socio-economic impact of genomics research by accelerating its translation to application or market; and,
  • Create and foster a more productive interface between Academia and Users.

3. Parameters

  • Up to $30 million is available from Genome Canada for this program
  • Genome Canada will provide support for small-scale proof-of-concept or pilot projects through to large-scale projects, ranging in size from $300,000 to $6 million in total project budget, with the Genome Canada investment not to exceed more than 1/3 of the total investment in the project by all parties. The remaining 2/3 must be secured through co-funding (see Section 9 and Appendix 2 for more details on co-funding)
  • Generally, the project term should be a minimum of six months to a maximum of three years. A shorter or longer term will be considered, but only if a strong rationale is provided.

4. Project Eligibility

To be eligible for funding, proposals must:

  • Respond to the objectives of the GAPP
  • Represent an active partnership between Academic(s) and User(s) (see Section 5);
  • Propose to develop, enhance or validate a genomics-derived solution(i.e., a product, tool or process whose origin is based in genomics);
  • Address key challenges or opportunities defined by the User that require a partnership with Academia (i.e., User “pull”); and
  • Focus on downstream R&D activities.

Examples of downstream R&D include proof-of-concept, validation or product/tool development projects for which there is a significant commercial market potential for the product, tool or process to be developed, enhanced or validated or other measurable impacts, such as uptake into practice or policy. The GAPP will support projects that have direct or indirect impacts on human health or have socio-economic benefits in other sectors of importance to Canada’s economy, e.g., agriculture, fisheries, forestry, energy, mining and the environment. The GAPP is intended to fund projects that enable the transfer of knowledge and technologies from Academia to Users and require support from Genome Canada to de-risk and incentivize follow-on investment from public and private partners. The GAPP is not intended to provide funding for:

  • Discovery research projects;
  • The commercial launch of a new product, tool or process; or,
  • Projects that would normally be funded solely by the User (e.g., industry).

5. Project Partners

There are two categories of partners in GAPP projects: Academics and Users. The roles and responsibilities of each Project Partner in arriving at the anticipated outcome(s) must be clearly defined. To be eligible for funding, each project must represent an active partnership between the Academic and the User. An active partnership is defined as one that leverages the resources of the Partners. It is expected that the Academic will provide expertise and knowledge with respect to the genomics-derived solution proposed. It is expected that the User must provide leadership in the identification of: the key issues to be solved; platforms, services or products to be developed; and, how these platforms or services would be exploited or moved forward. Partners must, individually or collectively, have a demonstrated track record of achieving results and translating discoveries to market or application. The proposal must be co-led by an Academic and an individual from the User organization(s) to demonstrate commitment, leadership and active partnership.

5.1. Academics

An Academic is defined as an independent investigator who is a faculty member employed by a Canadian post-secondary organization or their affiliated institutions including hospitals and research institutes. Researchers from not-for-profit organizations may be considered the Academic Project Partner if the organization has an explicit research mandate.

5.2. Users

Users include companies, industry consortia, government departments or agencies, or not-for-profits that have a credible plan for exploiting project results for the socio-economic benefit of Canada. The User must show that it has the expertise and resources to put the plan into effect or the means, as well as the intention, to acquire this capacity.

5.2.1. Company

A company is defined as a private or public, Canadian- or foreign-owned organization that derives the majority of its revenues from the sale of products and services and not from government aid. Small or start-up companies (companies in the R&D phase) that have sound business plans may be accepted as Users. For researcher-owned companies, the company must demonstrate that it has its own facilities and staff, physically separated from the academic researcher's laboratory (e.g., located in a university incubator facility or off campus).

5.2.2. Other Users

Other Users, including government departments and agencies, industry consortia and not-for-profits are eligible if they are in a position to exploit the results of the project in a way that results in significant socio-economic benefit to Canada.

6. Socio-Economic Benefits

The proposed socio-economic benefits to Canada must be significant, e.g., providing a competitive advantage to Canadian industry, improving public policy, or enhancing the cost-effectiveness of the healthcare system.

All proposals must describe, with supporting evidence and using clearly defined and quantifiable milestones:

  • The deliverable(s) to be realized by the end of the project;
  • a plan which explains the next steps of how the deliverables from the project will be transferred, disseminated, used, and/or applied to realize the socio-economic benefits in as short a time as possible following completion of the project (i.e. within 3-5 years);
  • Who will benefit from the project, including how the deliverables will benefit the User partner;
  • The market potential for the product, tool or process to be developed or other measurable impact; and,
  • For applicable projects, e.g., those targeting commercialization, how the project deliverables will incentivize follow-on investment from public and/or private partners, enable rapid progress towards the marketplace, and ensure further return on investment.

Proposals must take into account any societal issues (environmental, economic, ethical, legal and social) that may impact the success of the project or potentially delay uptake into practice. See Appendix 1 for more details on all review criteria.

7. Intellectual Property

 

As negotiation of issues related to intellectual property (IP) is anticipated to be critical to the finalization of contracts between   the Academic(s) and the User(s), at the time of submission of a full proposal, applicants will be required to provide a non-legally binding   Term Sheet. The Term Sheet must address the following issues:

  • Ownership of ‘foreground’ IP generated by the project;
  • Rights to use ‘background’ IP required for use in the project;
  • Licences to use foreground and background IP to the different project participants;
  • Management issues related to foreground IP (such as patent expenses, patenting decisions, dividing fields and scopes of use); and,
  • Risk management issues (what special risks might be present in this project and on which project participant do those risks fall).
 

Genome Canada does not take an ownership stake in project IP; however, in funding projects within GAPP, Genome Canada expects any intellectual   property created or developed within a Project to be exploited, including licensing, in a way that maximizes benefits for Canada. Ownership   of IP created or acquired as part of projects in which Genome Canada is directly or indirectly involved shall be in accordance with each of   the participants’ (i.e., Federal or Provincial government departments or Crown Corporations, private sector companies, universities,   research hospitals or any other participants) internal IP policies and Provincial and or Federal legislation, if applicable   (refer to Genome Canada’s Intellectual Property Policy). Applicants should also contact   their Genome Centre for information on specific Genome Centre guidelines related to IP.

 

8. Application Process

 

There is a two-stage application process for this program:

  1. Expression of Interest (EOI)
  2. Full Proposal
 

EOIs and full proposals must be submitted to Genome Canada through a Genome Centre (see Contacts, Section 10) and will be accepted on a   rolling intake basis, until all funding has been committed. The application process may be adjusted where warranted by relevant factors   such as the level of interest in the program. Any changes will be rapidly communicated through Genome Canada’s website and through the   Genome Centres.

 

8.1. Expression of Interest

 

Applicants are required to submit an Expression of Interest (EOI) to Genome Canada (through their Genome Centre). The EOI will be reviewed    by the Genomic Applications Programs Portfolio Manager (GAP PM) to determine eligibility for the program. Applicants will normally be    informed within two weeks whether their application is considered eligible, the timing of upcoming meetings of the Core Evaluation Team    (CET) and the deadlines for submission of a full proposal for consideration at each meeting.

EOI submissions to the program will be accepted on or after July 29, 2013. For details about the timing of upcoming CET meetings and deadlines for submission of full proposals, please refer to the Timelines available on Genome Canada’s website.

8.2. Full Proposal

The full proposals will first be reviewed by the GAP PM. A final check for eligibility will be carried out as well as an assessment as to the extent to which the proposal addresses all the Evaluation Criteria (refer to Appendix 1). Based on this evaluation, the GAP PM will determine whether the proposal is ready to undergo a Due Diligence review or whether further development is required by the applicants and Genome Centres.

8.2.1. Due Diligence

The Due Diligence will be undertaken by a small team of experts, specifically selected based on their expertise and experience in reviewing the financial, management and technical aspects of proposals such as those being submitted to this program. They will assess the proposal based on the Evaluation Criteria (see Appendix 1) and make recommendations to the CET. In cases where a thorough Due Diligence has been undertaken by the User, co-funder or another organization the GAP PM will determine whether it covers the same criteria and is sufficient. If the Due Diligence undertaken by the other organization is deemed sufficient, the proposal and Due Diligence reports may be forwarded directly by the GAP PM to the CET for consideration.

8.2.2. Core Evaluation Team

Genome Canada will establish a CET composed of external experts with the expertise in business development, commercialization, public policy, socio-economic benefit analysis, IP, financing, venture capital, etc. The CET will meet quarterly to review the proposals and the reports from the Due Diligence reviewers and make recommendations to Genome Canada regarding funding. The CET will also be involved in the ongoing monitoring of funded projects, as described in Appendix 2, Section 3.5.

9. Eligible Costs and Co-Funding

The main categories of eligible costs are: i) salaries and benefits, ii) consumables, iii) equipment, iv) administrative costs and iv) services from others. Genome Canada funds may be used to cover eligible costs incurred by the Project, with the exception of costs incurred outside Canada or within organizations that are not eligible to receive Genome Canada funding, i.e., companies or federal government departments and agencies.

Genome Canada will invest up to 1/3 of the funding required to cover eligible costs; the remaining 2/3 must be secured through co-funding with at least 1/3 provided by the User. The Genome Centres, working with the applicants, are responsible for securing co-funding. Co-funding must be for new or incremental activities that are an integral part of the Genome Canada approved project.

For more details on eligible costs and co-funding, refer to Appendix 2.

10. Contacts

Shelley King Genome Atlantic 902-421-5646 sking@genomeatlantic.ca
Catalina Lopez-Correa Genome Québec 514-398-0668 x 203 clopez@genomequebec.com
Rhonda Tannenbaum Ontario Genomics Institute 416-673-6586 rtannenbaum@ontariogenomics.ca
Chris Barker Genome Prairie 306-966-2799 cbarker@genomeprairie.ca
Gijs Van Rooijen Genome Alberta 403-210-5253 vanrooijen@genomealberta.ca
Gabe Kalmar Genome British Columbia 604-637-4374 gkalmar@genomebc.ca

Appendix 1. Evaluation Criteria

1. Eligibility Criteria

The proposal must:

  • Respond to the objectives of the GAPP
  • Represent an active partnership between Academic(s) and User(s)
  • Propose to develop, enhance or validate a genomics-derived solution, i.e., a product, tool or process whose origin is based in genomics
  • Address key challenges or opportunities defined by the User that require a partnership with Academia (User “pull”); and,
  • Focus on downstream R&D activities.

2. Due Diligence Criteria

2.1. Technical Aspects

  • Feasibility of the technical aspects of the proposal
  • Suitability of the available facilities, equipment and services for carrying out the project
  • Technical expertise of team
  • Ability to achieve deliverables in timeframe proposed
  • Degree to which the proposal enables the transfer of knowledge and technologies from Academia to the User community

2.2. User Relevance and Benefits to Canada

  • Provides significant socio-economic benefit to Canada in the near term (i.e., three to five years), by, for example, providing a competitive advantage to Canadian industry, improving public policy, enhancing the cost-effectiveness of the healthcare system, etc.
  • Significant market potential for the application, or other measurable impact
  • The next steps after the end of the project are well-defined such that the deliverables of the project are likely to be exploited for the socio-economic benefit of Canada in the near term.
  • Extent to which the commercialization strategy is well-defined and reasonable, including IP handling. If the application is not commercial, how well defined and reasonable is the strategy for uptake into policy or practice?
  • Reasonableness of the IP Term Sheet

2.3. Ability to Deliver on Objectives

  • Credibility of plan proposed by User for exploiting results of the project for the socio-economic benefit of Canada
  • Expertise and resources of the User to put the plan into effect, or the means, as well as the intention, to acquire this capacity
  • Extent to which the project team has all the required expertise to address the defined objectives competently and to complete the project successfully
  • Extent to which the impediments to application or uptake of the product, tool or process are addressed, e.g., regulatory hurdles or societal aspects

2.4. Management and Financial Aspects

  • Quality of the management team
  • Effectiveness of the management plan with respect to project governance, accountabilities of personnel, and processes for decision- making on research direction and strategy for realizing benefits
  • Milestones proposed are well-defined and quantifiable. Go/no go milestones are clearly articulated
  • Reasonableness of the proposed budget in terms of the anticipated level of effort and deliverables
  • Extent to which the proposal provides assurance that expenditures from a funded project will be closely and critically monitored
  • User is providing at least 1/3 of the co-funding
  • Extent to which the proposed co-funding plan is well-documented, eligible and feasible
  • Proposed co-funding is integrated with and directly supports the objectives of the project
  • Likelihood that all the co-funding will be secured at the time of release of funds

Appendix 2. Guidelines for GAPP Projects

1. Project Partners

Academic Project Leader

Each project must identify a Project Leader from an Academic Institution (see 5.1. Academics of the Investment Strategy). The Academic Project Leader is responsible for the intellectual direction of the proposed project and assumes administrative and financial responsibility for funds that will be paid to his/her institution.

User Project Leader

In addition to the Academic Project Leader, teams must identify a Project Leader from the User partner (see 5.2. Users in the Investment Strategy) organization to demonstrate commitment, leadership and active partnership. The User Project Leader is also responsible for the intellectual direction of the proposed project and assumes administrative and financial responsibility for the expenses incurred within their organization. The User Project Leader must be in a position to influence decisions made by the User organization and dedicate sufficient time to the project to be actively involved in its intellectual direction. The Academic Project Leader and the User Project Leader cannot be the same person.

Academic Co-Applicant

An Academic Co-applicant is a team member from an academic institution who makes a substantial contribution to the proposed project and who will be involved in the day-to-day execution of the project.

User Co-Applicant

A User Co-applicant is a team member from a User organization who makes a substantial contribution to the proposed project and who will be involved in the day-to-day execution of the project.

Collaborator

A Collaborator is an individual who is not involved in the day-to-day execution of the project but whose role is to provide a specific service or expertise (e.g., access to equipment, provision of specific reagents, training in a specialized technique, statistical analysis, access to a patient population, etc.).

2. Funding

2.1. Eligibility of Investigators, Institutions and Organizations

Genome Canada funding is restricted to work performed within Genome Canada eligible institutions, i.e., Genome Canada will not support work to be undertaken outside Canada, in for-profit organizations or in federal laboratories, except for costs incurred based on a reasonable fee-for-service arrangement or contract.

Genome Canada funds can be awarded to investigators affiliated with the following institutions and organizations:

  • Canadian post-secondary organizations and their affiliated institutions including hospitals and research institutes;
  • Canadian non-federal government departments or agencies and not-for-profit organizations (including community or charitable organizations) with an explicit research or knowledge-translation mandate.

2.2 Eligible Costs

Eligible costs are defined as reasonable costs for items that directly support the objectives of the Genome Canada approved project. Budgets must NOT include items for which funding has already been approved from other sources, unless the request for funding of these items was specifically made to support activities in the Genome Canada project and they meet all other eligibility criteria. Expenses funded through Genome Canada must be incurred after the Notice of Award (NOA) to be considered as eligible costs. However, expenses covered by eligible co-funding incurred up to three months prior to the NOA may be considered eligible costs.

Eligible costs may include the following:

Salaries

  • Salaries and benefits for project team members (note that salaries of independent investigators who are faculty members of academic institutions or in a management role in a User organization are not considered eligible costs).
  • The actual benefit rates as charged by the host organization. For benefit rates that exceed 20% of the employee’s salary supporting documentation (such as a letter from the organization`s human resources department) must be provided.
  • The actual cost of release time from teaching and clinical duties, if supported by a letter from the host institution.
  • Annual inflation for salary expenditures in the second and later years of the project at actual rates as charged by the organization; for inflationary increases exceeding 1.5% of total salary and benefits, supporting documentation must be provided.

Equipment

  • Equipment is defined as any item (or interrelated collection of items comprising a system) which is used wholly or in part for the work proposed and meets all three of the following conditions: 1) nonexpendable tangible property; 2) having a useful life of more than one year; and, 3) a cost of $2,000 or more.
  • Small equipment items having a value of less than or equal to $50,000 each are eligible; more expensive items will only be covered in exceptional circumstances when the equipment is crucial to the success of the project and the equipment cannot reasonably be funded by other sources or accessed by other means.

Please note that the costs of equipment maintenance contracts and general maintenance of research infrastructure are considered consumables expenses (see below).

Consumables

  • Material and supplies: includes items that meet at least one of the following conditions: 1) expendable tangible property; 2) useful life of one year or less; or, 3) a cost of less than $2,000. As an example, a laptop computer that costs less than $2,000 would be considered a consumable even though it is a nonexpendable tangible item with a useful life of more than one year.
  • The consumables category also includes items such as equipment maintenance contracts and general maintenance of research infrastructure, travel directly related to the conduct of the project, and materials and supplies related to the direct costs of application or commercialization activities (e.g., costs associated with advancing development of products and technology, business case development, market research and technology evaluation).

General and Administrative Costs

  • Administrative costs can include, for example, travel for project team members related to the management of the project (e.g., project team meetings) and project-related conferences, communications and public outreach activities, website maintenance, office expenses, costs associated with the preparation of reports.
  • Administrative costs must not exceed five percent (5%) of the non-administrative costs of the budget.

Services from Others

  • The costs related to services provided by fee-for service providers.
  • Expenses related to application or commercialization activities provided on a fee-for-service basis (e.g., patent registration and filing costs, costs associated with advancing development of products and technology, business case development, market research and technology evaluation).

Examples of ineligible costs include the following:

  • Payments to foreign persons, for example, salaries and benefits of project team members;
  • Indirect costs to the project, including institutional overhead costs;
  • Rent, renovation or construction of buildings or facilities, and the opportunity cost of using existing infrastructure;
  • Incorporation and legal costs associated with a new spin-off or company; and,
  • Inflation applied to consumables, equipment, general & administrative costs or services from others.

2.3 Co-funding

Genome Canada will invest up to 1/3 of the investment required to cover eligible costs; the remaining 2/3 must be secured through co-funding with at least 1/3 provided by the User. The co-funding provided by the User may be derived from their own resources or from funds provided to the User by another source. All co-funding must be secured before funds can be released to the project. The Genome Centres, working with the applicants, are responsible for securing co-funding.

2.3.1 Sources of Co-funding

Eligible co-funding sources include:

  • Companies
  • Venture capital or other investment funds.
  • An industry consortium
  • Institutional funds, trust funds, or foundations
  • Charities and philanthropic organizations
  • Departments and agencies of the federal government (e.g., Natural Resources Canada, Agriculture and AgriFood Canada, the Canada Foundation for Innovation and Economic Development Agencies)
  • Centres of Excellence for Commercialization and Research (CECRs)
  • Departments and agencies of provincial and municipal governments
  • Voluntary organizations
  • Individuals

Ineligible co-funding sources include:

  • Canadian Institutes of Health Research (CIHR)
  • Natural Sciences and Engineering Research Council (NSERC)
  • Social Sciences and Humanities Research Council (SSHRC)
  • Canada Research Chairs (CRC)
  • Networks of Centres of Excellence (NCEs); with the exception that CECRs are considered eligible for this program, see above

2.3.2 Co-funding Requirements

Co-funding must be for eligible costs that represent new or incremental activities that are an integral part of the Genome Canada approved project (see Eligible Costs, Section 2.2) in order to be considered as an eligible co-funding source.

In-kind contributions, defined as non-cash eligible budget items which can be given as cash value (such as salaries for company personnel working on the project) may be considered as co-funding if:

  • The value can be reasonably determined and supported by documentation from the co-funder; and,
  • The expenditure represents an item that would otherwise have to be acquired with cash. However, this excludes the cost of pre-existing facilities or equipment (i.e., budgets cannot include the opportunity cost of space or equipment).

The value of existing IP transferred to a project is NOT considered eligible co-funding unless it is a contribution by a supplier of IP (e.g., a software license that would otherwise have to be acquired from a third party supplier). Such items must be supported by appropriate documentation from the supplier’s head office.

Suppliers’ discounts are not considered eligible co-funding.

Funding to support the indirect costs of a project (including overhead) are not eligible.

2.3.3 Documentation Required to Support Co-funding

Full applications must include complete documentation to support proposed co-funding. This may be in the form of a letter of commitment or an agreement defining the terms and conditions of proposed co-funding. In addition, the project must provide a description of how the co-funding will directly support the objectives of the Genome Canada project. In general, co-funders must explicitly acknowledge the use of funds to co-fund the Genome Canada projects.

The following provides specific examples of documentation required, depending upon the co-funding source, or type:

Organizations, including companies, charities, and philanthropic organizations:

  • Documentation and supporting information which clearly demonstrates the organization’s level and terms of commitment to the project. Appropriate documentation could include but is not limited to a Board Resolution, and/or, a letter from the organization’s CEO, legal counsel or Corporate Secretary.
  • Appropriate and reasonable documentation supporting the organization’s financial viability and its ability to deliver on the co-funding. Depending on the organization and the level of funding being committed, documentation could include: A full set of the organization’s most recent audited financial statements, including the Auditor’s Report, a Balance Sheet, Income Statement, Statement of Cash Flows and Notes to the Financial Statements
  • In the case where the audited statements are more than three months old, a full set of the organization’s financial statements (prepared within three months prior to the application) including a Balance Sheet, Income Statement, Statement of Cash Flows and Notes to the Financial Statements; and,
  • Any other information or documentation (e.g., press releases announcing significant new financing, cash flow projections, etc.) which provides credible support to the organization’s financial viability and ability to fulfill its co-funding commitments.

From a Provincial government

  • Confirmation that the province will provide co-funding
  • The amount anticipated
  • A list of other projects currently submitted to the GAPP that the government will support, including the project tracking number, the name of the Project Leaders, the title of the project, and the amount of the request from the government;
  • A description of the process that will take place once Genome Canada announces awards, including timelines for decisions and, if appropriate, confirmation that the government will accept Genome Canada's review process; and,
  • A letter signed by a high-ranking provincial government official with appropriate authority.

From a funding agency

  • A copy of the full application
  • Project summary
  • Detailed budget; and
  • Notice of award (if applicable)

Documentation must clearly demonstrate that funding is being used for eligible costs included in the budget of the Genome Canada approved project.

In-kind contributions

  • A clear rationale and calculation of how the value of the contribution was determined (including documentation to support all assumptions, price lists, quotes from suppliers, letters supporting same, etc.).

All in-kind contributions must be auditable by outside experts and clear explanations are required if there are any discrepancies between the value outlined in the co-funding document and the budget. Examples of supporting documentation to support in-kind co-funding include:

  • Salaries
    • Each in-kind salary line must be detailed by position as required in the budget template and represent the actual salary and benefits of the position in accordance with the applicable salary provisions of Eligible Costs in section 2.2.
  • Consumables
    • Documentation that indicates the actual cost to the User or co-funder to acquire the consumables or documentation that indicates the price that would be typically paid for the item(s) on the commercial market.
  • Equipment and Software
    • Letter from a senior official of the vendor that shows the price that the customer would typically have paid for the equipment or software (net of typical discounts including institutional discounts which are not eligible as co-funding)
    • For custom-made or used equipment, a third party valuation will normally be required
    • For previously developed custom-made software or IP, only new costs are eligible.
  • Samples and Other Biological Resources
    • If samples are typically available at no cost then there is no cost of acquiring such samples and as a result no value can be deemed to be co-funding
    • If samples are typically sold, then any proposed contribution would require the same documentation as equipment and software.

3. Administration

3.1 Project Readiness

Leader(s) of approved projects must meet, through formally submitted documentation, all relevant conditions that may be specified in the Notice of Award (NOA) received from Genome Canada and be in a position to receive Genome Canada funding no later than three months after the effective date of the NOA. Genome Canada reserves the right to withdraw funding for any approved project that is not ready to receive funding at that time.

3.2 Conditions for Release of Genome Canada Funds

Before funds can be disbursed the conditions for funding must be satisfied which normally include, but are not restricted to:

  • Signed agreements between the Genome Centre and the lead organization, the project team and the co-funding partners. The agreements must clearly demonstrate agreement among the relevant parties, on all significant issues including but not limited to, the nature of financial contributions, IP ownership and management in alignment with the Term Sheet submitted in the proposal, data release, the commercialization process, the funding term, a termination policy, financial and administrative policies, and quarterly reporting of expenses and co-funding status, etc. The agreements must be in compliance with the agreement between Genome Canada and the lead Genome Centre.
  • A revised budget, as well as revised objectives and milestones, if adjustments were made during the review process;
  • Secured co-funding (received or firmly committed) for the project (i.e. 100% of co-funding). Genome Canada reserves the right to withdraw its funding for any approved project that does not meet this requirement or if there is a substantial change in a project’s co-funding status.
  • Appropriate certification for proposals performing research involving human subjects, human stem cells, animals, biohazards, radioactive materials or possible effects on the environment are in place.
  • A publication policy which includes a commitment to comply with Genome Canada’s policy on Access to Research Publications.
  • A commitment to acknowledge the contribution of the Government of Canada through Genome Canada and the lead Genome Centre, as well as all other relevant funders, in publications and all communications in compliance with Genome Canada’s Brand Standards Guide

3.3 Management of Funding

  • The agreement between Genome Canada and the Genome Centre will reference financial commitments from other persons as well as other financial requirements.
  • As the needs and circumstances of each Centre, the team and partner organizations may differ, the contracts between these partners will be negotiated individually and need not be identical, but should apply the same general principles defined in the agreement between Genome Canada and the Genome Centres. Genome Canada’s share of the funding for approved projects will flow from Genome Canada to the Centres. The Genome Centres will manage (e.g., disburse, monitor and report on) the funds for the project.
  • Genome Canada’s contributions can be adjusted to accommodate the timing of the expected receipt of funds from co-funding partners.
  • Genome Canada provides funding up to the approved quarterly contribution, a quarter “in advance”, subject to receipt of quarterly reports of expenditures (from both Genome Canada and co-funding sources), including actuals to the previous quarter, estimates for the current quarter, and forecasts for the quarter of the advance. Subsequent quarterly advances may be adjusted to account for any unused funding. The final settlement of advances is based on Genome Canada’s pro rata share of actual expenditures, as per the Genome Canada’s contribution ratio on the latest approved budget.
  • The financial status of co-funding (domestic and international) must be reported on a quarterly basis.

3.4 Accountability, Reporting and Performance Measurement

Funded projects must submit to their lead Genome Centre on a quarterly basis, information and data as prescribed by the Centre and the Genome Canada in terms of timing, format and content, which will allow for the on-going assessment and monitoring of their performance. Funded projects must also agree to participate in and provide information for any evaluation-type activities that may be undertaken from time to time by Genome Canada or the Genome Centre, for up to five years subsequent to the end date of the project.

3.5 Monitoring, Maximizing Impact and Management of Changes to Funded Projects

In order to ensure projects are meeting their milestones and maximize the likelihood of success of funded projects, the lead Genome Centre and the Genome Canada GAP PM will work together to monitor and advise the projects on an ongoing basis. In addition, project teams will be required to submit quarterly reports to their lead Genome Centre, including reporting on progress towards meeting their milestones. For projects in which the investment from Genome Canada is less than $1 million and there was no go/no go gate in that quarter, the GAP PM will review the progress report and provide feedback directly to the project via the lead Genome Centre. For projects where the investment by Genome Canada is greater than $1 million or for any project where there is a go/no go milestone during that quarter, the progress reports will be forwarded to the Core Evaluation Team. Each quarter, the CET will make recommendations to Genome Canada regarding whether funding should be continued, modified or cancelled for those projects.

Over the term of a Genome Canada funded project, changes to the scientific, managerial or financial conditions of funding initially approved by Genome Canada must be discussed in advance with the Lead Genome Centre and the Genome Canada GAP Portfolio Manager. Changes may be submitted to the CET for review. Final approval of changes will be required from the Lead Genome Centre and Genome Canada.

3.6 Final Reports

Within three (3) months of the completion of the projects, each project will be required to submit to its Genome Centre a final report that includes a description of the accomplishments of the project relative to the approved objectives as well as a detailed financial report in a format as determined by Genome Canada. A percentage of the final payment will be held back pending receipt and approval of the Final Report.

Timelines

EOIs will be accepted on or after July 29, 2013

Cut-off dates for submission of full proposals to be considered at upcoming Core Evaluation Team (CET) meetings are:

  • October 11, 2013 (for consideration at mid-November 2013 CET meeting)
  • January 10, 2014 (for consideration at mid-February 2014 CET meeting)

[1] The term genomics is defined here as the comprehensive study, using high throughput technologies, of the genetic information of a cell or organism, including the function of specific genes, their interactions with each other and the activation and suppression of genes. For purposes of describing Genome Canada’s mandate it also includes related disciplines such as bioinformatics, epigenomics, metabolomics, metagenomics, nutrigenomics, pharmacogenomics, proteomics and transcriptomics.